Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 6, 2023; 11(7): 1498-1505
Published online Mar 6, 2023. doi: 10.12998/wjcc.v11.i7.1498
Successful multidisciplinary therapy for a patient with liver metastasis from ascending colon adenocarcinoma: A case report and review of literature
Xiao-Rong Tan, Juan Li, Hua-Wei Chen, Wei Luo, Nan Jiang, Zheng-Bo Wang, Shuai Wang
Xiao-Rong Tan, Oncological Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Xinjiang Medical University, School/Hospital of Stomatology Xinjiang Medical University, Urumqi 830054, Xinjiang Uygur Autonomous Region, China
Juan Li, Hua-Wei Chen, Wei Luo, Nan Jiang, Zheng-Bo Wang, Shuai Wang, Department of Oncology, Daping Hospital, Army Medical University, Chongqing 400042, China
Author contributions: Tan XR and Wang S were the patient's oncologists, reviewed the literature, and contributed to drafting the manuscript; Li J and Wang S were responsible for revising the manuscript for important intellectual content; Chen HW and Jiang N reviewed the literature and contributed to drafting the manuscript; Wang ZB and Luo W analyzed and interpreted the imaging findings; all authors issued final approval for the version to be submitted.
Informed consent statement: A written informed consent was obtained from the patient for publication of this case report.
Conflict-of-interest statement: All the authors have nothing to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shuai Wang, MS, Associate Chief Physician, Department of Oncology, Daping Hospital, Army Medical University, No. 10 Changjiang Branch Road, Yuzhong District, Chongqing 400042, China. sharondenise_mine@163.com
Received: September 20, 2022
Peer-review started: September 20, 2022
First decision: December 26, 2022
Revised: January 7, 2023
Accepted: February 10, 2023
Article in press: February 10, 2023
Published online: March 6, 2023
Processing time: 162 Days and 21.8 Hours
Core Tip

Core Tip: We report a multidisciplinary strategy, including 5-fluorouracil/Leucovorin/oxaliplatin/Endostar® (mFOLFOX6 plus Endostar®) and transcatheter arterial chemoembolization, that may help improve resectability of initially unresectable colorectal liver metastasis (CRLM) and achieve pathologically complete response (pCR). After the recurrence of liver metastasis, the patient received TACE comprising irinotecan/Leucovorin/fluorouracil therapy plus Endostar® and was treated with γ-knife. The patient's overall survival time exceeded 9 years. To date, this is the first case that mFOLFOX6 combined with Endostar® in conversion therapy of initially unresectable CRLM and liver metastases that achieved pCR. Our study implies that Endostar® has a potential value in conversion therapy and combination therapy of initially unresectable CRLM.